Lymphoma subtype distribution (Hodgkin’s, B-cell and T-cell lymphomas) in patients with RA in treatment groups. ARTIS and BSRBR-RA, both with more than 30 lymphomas in the bionaïve and TNFi groups, are shown separately to describe the robustness of the results
| N total | Hodgkin’s | B cell | T cell | NOS | |||||||
| n | % | 95% CI | n | % | 95% CI | n | % | 95% CI | N excluded | ||
| Bionaïve | |||||||||||
| ARTIS | 197 | 13 | 6.6 | 3.3 to 11.8 | 174 | 88.3 | 82.1 to 93.0 | 10 | 5.1 | 2.6 to 8.8 | 19 |
| BSRBR | 30 | 5 | 16.7 | 5.1 to 37.0 | 22 | 73.3 | 50.9 to 88.6 | 3 | 10.0 | 1.8 to 29.1 | 4 |
| Other | 31 | 3 | 9.7 | 1.8 to 28.6 | 24 | 77.4 | 55.3 to 91.2 | 4 | 12.9 | 3.2 to 32.5 | 7 |
| Total | 258 | 21 | 8.1 | 4.7 to 12.9 | 220 | 85.3 | 79.3 to 90.0 | 17 | 6.6 | 3.6 to 11.2 | 30 |
| TNFi | |||||||||||
| ARTIS | 52 | 6 | 11.5 | 4.0 to 26.2 | 40 | 76.9 | 61.1 to 88.3 | 6 | 11.5 | 4.0 to 26.2 | 7 |
| BSRBR | 77 | 11 | 14.3 | 6.5 to 25.9 | 63 | 81.8 | 69.4 to 90.6 | 3 | 3.9 | 0.7 to 12.1 | 10 |
| Other | 73 | 7 | 9.6 | 3.6 to 20.4 | 61 | 83.6 | 71.3 to 91.8 | 5 | 6.9 | 2.0 to 17.0 | 11 |
| Total | 202 | 24 | 11.9 | 7.0 to 18.3 | 164 | 81.2 | 74.1 to 87.3 | 14 | 6.9 | 3.3 to 12.3 | 28 |
| Rituximab | 6 | 0 | 0 | 0 to 50.0 | 5 | 83.3 | 32.9 to 99.7 | 1 | 16.7 | 0.3 to 67.2 | 0 |
| Tocilizumab | 5 | 0 | 0 | 0 to 56.0 | 5 | 100 | 44.0 to 100 | 0 | 0 | 0 to 56.0 | 1 |
| Abatacept | 3 | 0 | 0 | 0 to 74.4 | 3 | 100 | 25.6 to 100 | 0 | 0 | 0 to 74.4 | 0 |
| RA total | 474 | 45 | 9.5 | 6.6 to 13.2 | 397 | 83.8 | 79.3 to 87.6 | 32 | 6.8 | 4.3 to 10.0 | 59 |
BSRBR-RA, British Society for Rheumatology Biologics Register for Rheumatoid Arthritis; NOS, not otherwise specified; RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor.